Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -251.91M | -263.30M | -258.42M | -264.52M | -299.09M |
| Total Depreciation and Amortization | 7.71M | 7.84M | 8.18M | 8.50M | 8.55M |
| Total Amortization of Deferred Charges | 2.24M | 2.29M | 2.35M | 2.43M | 2.48M |
| Total Other Non-Cash Items | 36.82M | 36.46M | 29.35M | 27.27M | 59.36M |
| Change in Net Operating Assets | 29.56M | 35.67M | 25.87M | 30.27M | 17.94M |
| Cash from Operations | -175.58M | -181.03M | -192.66M | -196.06M | -210.77M |
| Capital Expenditure | -266.00K | -266.00K | -256.00K | -312.00K | -503.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -266.00K | -266.00K | -256.00K | -312.00K | -503.00K |
| Total Debt Issued | 33.89M | 38.29M | 42.88M | 47.46M | 109.51M |
| Total Debt Repaid | 0.00 | -64.42M | -64.81M | -65.20M | -65.58M |
| Issuance of Common Stock | 32.46M | 73.97M | 146.72M | 118.11M | 115.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -146.00K | -213.00K | -268.00K |
| Cash from Financing | 66.35M | 47.84M | 124.64M | 100.16M | 158.83M |
| Foreign Exchange rate Adjustments | -4.13M | -2.17M | -401.00K | -589.00K | -309.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.63M | -135.63M | -68.68M | -96.80M | -52.75M |
